GH001 is a small molecule commercialized by GH Research, with a leading Phase II program in Post Partum Depression (Maternal Depression / Postnatal Depression). According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of GH001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GH001 is expected to reach an annual total of $198 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GH-001 is under development for the treatment of treatment-resistant depression, major depressive disorder, bipolar II disorder, post partum depression and other psychiatric diseases. The drug candidate is a 5-methoxy-dimethyltryptamine (5-MEO-DMT). The drug candidate is a drug-device combination. It is administered through the inhalational route. It acts by targeting serotonin 5 HT1A and 5HT2A.
GH Research Overview
GH Research biopharmaceutical company developing novel therapies for psychiatric and neurological disorders. The company has desigend its proprietary inhalable 5-MeO-DMT for depression. GH Research is headquartered in Dublin, Ireland.
The operating loss of the company was US$15.1 million in FY2021, compared to an operating loss of US$0.5 million in FY2020. The net loss of the company was US$9.2 million in FY2021, compared to a net loss of US$0.5 million in FY2020.
For a complete picture of GH001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.